Laura Riva

This study evaluates CMX990, a coronavirus Mpro inhibitor, showing broad antiviral activity against multiple coronaviruses and superior pharmacologic properties compared to existing inhibitors.

This paper describes the development of orally bioavailable SARS-CoV-2 protease inhibitors with a hydroxymethyl ketone warhead, showing improved potency and bioavailability compared to previous compounds.

This study investigates the antiviral activity and mechanism of 4'-fluoroadenosine against viral and host polymerases, showing broad-spectrum inhibition and potential for drug development.

This study uses a primary human stem cell-based airway model to screen 2100 compounds and identifies a small molecule effective against SARS-CoV-2 and its Omicron variant.

This study identifies critical human host factors involved in SARS-CoV-2 multicycle replication through a genome-scale siRNA screen and validates potential antiviral targets.

This paper introduces CMX990, a potent SARS-CoV-2 3CL protease inhibitor with improved potency and clearance compared to nirmatrelvir, advancing to Phase 1 clinical trials.

The paper predicts anti-SARS-CoV-2 targets by identifying synthetic lethal partners of host genes altered during infection, validated through CRISPR-Cas9 screens and siRNA experiments.

The paper identifies a two-factor authentication mechanism used by the innate immune system to detect low-abundance HIV-1 DNA through PQBP1-mediated capsid recognition and cGAS recruitment.

The paper uses genome-scale metabolic modeling to identify SARS-CoV-2-induced metabolic changes and predict antiviral targets validated through drug and genetic screens.